XOMA Corporation (XOMAO)
Oxford Ledge is still expanding full research coverage of XOMAO. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
XOMA funds biotech drug development by acquiring rights to future milestone and royalty payments, operating a diversified portfolio of over 120 assets.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Termination of material agreement; Completion of acquisition or disposition; Delisting / transfer of listing; 3.03; 5.01; Departure/election of directors or officers; Shareholder vote results; Other material event; Financial statements and exhibits 2026-07-14
- 8-K Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-06-12
- 8-K Departure/election of directors or officers; Amendments to articles or bylaws; Shareholder vote results; Financial statements and exhibits 2026-05-22
- 8-K Entry into material agreement; Financial statements and exhibits 2026-05-18
- 10-Q Quarterly financial report (unaudited) 2026-05-12
Source: SEC EDGAR.
Annual results
5 years of annual figures for XOMAO, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $52.1M | $31.7M | $1.46 |
| 2024 | $28.5M | -$13.8M | -$1.65 |
| 2023 | $4.8M | -$40.8M | -$4.04 |
| 2022 | $6.0M | -$17.1M | — |
| 2021 | $38.2M | $15.8M | $0.65 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
- Open XOMAO in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.